States alleged that SmithKline Beecham, manufacturer of the anti-depressant Paxil, had filed patents for allegedly different fomulas of essentially the same product. The states alleged that the defendant filed a series of meritless infringement lawsuits against generic manufacturers. Generic entry was prevented for six years. The states settled their proprietary claims for $14 million. Two previous setlements totalling $165 million covered consumers and pharmacy purchasers.